Form 8-K - Current report:
SEC Accession No. 0001171843-20-003680
Filing Date
2020-05-13
Accepted
2020-05-13 16:15:14
Documents
5
Period of Report
2020-05-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_051320.htm 8-K 37516
2 EXHIBIT 3.1 exh_31.htm EX-3.1 11921
3 EXHIBIT 3.2 exh_32.htm EX-3.2 8452
4 EXHIBIT 10.1 exh_101.htm EX-10.1 149465
5 EXHIBIT 10.2 exh_102.htm EX-10.2 46383
  Complete submission text file 0001171843-20-003680.txt   255160
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 20873332
SIC: 2836 Biological Products, (No Diagnostic Substances)